We are live on
!
Find out more
CM
Crestline Management Portfolio holdings
AUM
$46.3M
1-Year Est. Return
48.82%
This Fund
S&P 500
This Quarter
Est. Return
-6.42%
1 Year Est. Return
+48.82%
3 Year Est. Return
+52.52%
5 Year Est. Return
+37.91%
10 Year Est. Return
+316.44%
AUM
$976M
AUM Growth
+$257M
(+36%)
Cap. Flow
+$279M
Cap. Flow
% of AUM
28.55%
Top 10 Holdings %
Top 10 Hldgs %
76.43%
Holding
234
New
114
Increased
26
Reduced
16
Closed
77
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Denali Therapeutics
DNLI
|
+$370M |
| 2 |
American International
AIG
|
+$8.49M |
| 3 |
Ameriprise Financial
AMP
|
+$7.55M |
| 4 |
T. Rowe Price
TROW
|
+$7.55M |
| 5 |
Visa
V
|
+$6.43M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
JUNO
Juno Therapeutics, Inc.
JUNO
|
+$85.7M |
| 2 |
FNB Corp
FNB
|
+$8.22M |
| 3 |
Travelers Companies
TRV
|
+$7.78M |
| 4 |
Sherwin-Williams
SHW
|
+$7.34M |
| 5 |
Willis Towers Watson
WTW
|
+$7.28M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 37.59% |
| 2 | Financials | 12.34% |
| 3 | Technology | 4.43% |
| 4 | Industrials | 4.41% |
| 5 | Consumer Discretionary | 1.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
Advanced Micro Devices
AMD
$776B
| $308K | 0.03% |
+30,000
| New | +$351K |
|
|
FG
152
DELISTED
FGL Holdings Ordinary Shares
FG
| $303K | 0.03% |
+30,084
| New | +$308K |
|
|
MNDT
153
DELISTED
Mandiant, Inc. Common Stock
MNDT
| $253K | 0.03% |
+17,830
| New | +$271K |
|
|
PAY
154
DELISTED
Verifone Systems Inc
PAY
| $252K | 0.03% |
+14,220
| New | +$264K |
|
155
Hewlett Packard
HPE
$63.4B
| $215K | 0.02% |
+15,000
| New | +$213K |
|
|
NPKI
156
NPK International
NPKI
$1.06B
| $211K | 0.02% |
+24,592
| New | +$223K |
|
157
Greenlight Captial
GLRE
$552M
| $202K | 0.02% |
+10,061
| New | +$219K |
|
158
Assurant
AIZ
$13.8B
| – | – |
-20,359
| Closed | -$1.95M |
|
159
Allstate
ALL
$68B
| – | – |
-61,349
| Closed | -$5.64M |
|
160
Associated Banc-Corp
ASB
$5.83B
| – | – |
-53,000
| Closed | -$1.28M |
|
161
Franklin Resources
BEN
$17.6B
| – | – |
-78,918
| Closed | -$3.51M |
|
162
Biogen
BIIB
$30B
| – | – |
-11,145
| Closed | -$3.49M |
|
|
BLUE
163
DELISTED
bluebird bio
BLUE
| – | – |
-972
| Closed | -$1.73M |
|
164
Bank of Hawaii
BOH
$3.15B
| – | – |
-24,000
| Closed | -$2M |
|
|
CADE
165
DELISTED
Cadence Bank
CADE
| – | – |
-30,000
| Closed | -$962K |
|
166
Cathay General Bancorp
CATY
$4.22B
| – | – |
-29,000
| Closed | -$1.17M |
|
|
CMA
167
DELISTED
Comerica
CMA
| – | – |
-47,000
| Closed | -$3.58M |
|
168
CSX Corp
CSX
$93.4B
| – | – |
-90,000
| Closed | -$1.63M |
|
169
DXC Technology
DXC
$1.82B
| – | – |
-37,179
| Closed | -$2.76M |
|
170
Euronet Worldwide
EEFT
$2.72B
| – | – |
-23,661
| Closed | -$2.24M |
|
171
Everest Group
EG
$14.5B
| – | – |
-12,479
| Closed | -$2.85M |
|
172
8x8 Inc
EGHT
$269M
| – | – |
-187,341
| Closed | -$2.53M |
|
|
ESPR
173
DELISTED
Esperion Therapeutics
ESPR
| – | – |
-26,350
| Closed | -$1.32M |
|
174
Fate Therapeutics
FATE
$286M
| – | – |
-24,174
| Closed | -$96K |
|
175
FedEx
FDX
$72.7B
| – | – |
-20,000
| Closed | -$4.51M |
|
Similar funds
MCMC
RRC
PCM
NPCM
FCM
EGI
IPHI
SM
Crestline Management's Q4 2017 Portfolio in Review
As of Q4 2017, Crestline Management held 234 positions worth $976M, up 36% from $719M the previous quarter. Its ten largest holdings account for 76% of the portfolio.
Crestline Management deployed $279M of net new capital in Q4 2017, opening 114 new positions and adding to 26 existing holdings. Its largest new stake was Denali Therapeutics: 20,574,298 shares worth $322M.
By sector, the portfolio is most concentrated in Healthcare at 38% of assets, up from 5.7% a quarter earlier, followed by Financials and Technology.
On the sell side, the largest reduction was Juno Therapeutics, Inc., an estimated $85.7M trimmed.
- Crestline Management's largest Q4 2017 buy was Denali Therapeutics: 20,574,298 shares worth $322M.
- Crestline Management added most to Ameriprise Financial in Q4 2017, an estimated $7.55M increase.
- Crestline Management's biggest Q4 2017 reduction was Juno Therapeutics, Inc., cutting an estimated $85.7M.
- Crestline Management fully exited FNB Corp in Q4 2017, selling an estimated $8.22M.
- Crestline Management's ten largest holdings make up 76% of its $976M portfolio in Q4 2017.
- Crestline Management opened 114 new positions and closed 77 in Q4 2017.
- Crestline Management's portfolio value rose 36% quarter-over-quarter to $976M.
Based on Crestline Management's 13F filing for Q4 2017, filed 14 Feb 2018.